• Annexin V-PE Reagent in CAR-T Cell Fate Mapping

  2026-08-20

  Annexin V-PE Reagent can do more than identify dying cells: it can help map target-cell killing, effector-cell fratricide, and assay-state transitions in CD38 CAR-T research. This article connects PS biology with structure-guided CAR affinity tuning while defining practical limits and controls.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance

  2026-08-19

  This study identifies RCN2 as a mechanistic driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance. It connects RCN2 to UBR5-dependent PPP2CA degradation and PI3K-AKT activation, providing a molecular framework for interpreting treatment failure and testing pathway-directed interventions.

• Resveratrol for SIRT1-Driven Neuroprotection

  2026-08-18

  Build a mechanistically grounded Resveratrol neuroprotection assay around SIRT1, mitochondrial biogenesis, and apoptosis rather than relying on viability alone. This workflow connects N2a prion-peptide injury models with practical formulation, controls, endpoint selection, and troubleshooting guidance.

• Deracoxib and Piroxicam in Canine Osteosarcoma

  2026-08-18

  The 2005 study by Royals and colleagues compared deracoxib and piroxicam across canine osteosarcoma and fibroblast cell lines, combining viability measurements with DNA-fragmentation analysis. Deracoxib showed broader and greater in vitro growth inhibition than piroxicam, but the effects occurred at concentrations above typical canine plasma exposure and were not accompanied by demonstrable apoptosis.

• Rocilinostat: An Assay-First HDAC6 Framework

  2026-08-17

  Rocilinostat (ACY-1215) enables selective HDAC6 perturbation while helping researchers distinguish cytoskeletal, viability, and cilia-related phenotypes. This assay-first framework connects multiple myeloma models with mechanistic lessons from SMPD4 developmental biology.

• Z-YVAD-FMK for Caspase-1 Pathway Studies

  2026-08-17

  Z-YVAD-FMK is a cell-permeable, irreversible caspase-1 inhibitor for separating inflammasome-driven pyroptosis from apoptosis and other death programs. This practical guide covers DMSO handling, dose-response design, gasdermin-centered readouts, and troubleshooting across cancer, inflammatory, and avian cell models.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-08-16

  The reference study identifies Polo-like kinase 1 (Plk1) as a direct inhibitor of p31comet-mediated mitotic checkpoint complex disassembly through phosphorylation at S102. Its findings provide a mechanistic explanation for how cells limit premature checkpoint silencing while chromosomes remain unattached, with implications for interpreting biochemical studies of mitotic control.

• GSK343 and the Next Layer of EZH2 Biology

  2026-08-15

  GSK343 offers a precise way to interrogate EZH2-driven chromatin repression while keeping translational claims anchored to measurable pharmacology. This article connects H3K27me3 biology, cancer-cell validation, and emerging APEX2–TERT findings to propose a disciplined framework for biomarker-led epigenetic research.

• Clarithromycin CYP3A Inhibition Workflow

  2026-08-15

  Build reproducible CYP3A inhibition assays with Clarithromycin using solvent-aware preparation, staged concentration testing, and pathway-specific controls. The workflow also shows how to distinguish a true drug-drug interaction signal from precipitation, vehicle effects, and assay nonlinearity in statin and cardiovascular pharmacokinetic studies.

• Fluorescein TSA Fluorescence System Kit Guide

  2026-08-14

  Learn how Fluorescein TSA Fluorescence System Kit, SKU K1050, can address weak endpoint signals in fixed-cell immunocytochemistry, immunohistochemistry, and in situ hybridization. This scenario-based guide covers assay compatibility, optimization, interpretation, storage, and practical vendor-selection criteria without overstating performance beyond the documented product specifications.

• Tetrandrine: From Calcium Flux to Translation

  2026-08-14

  Tetrandrine is more than a natural-product catalog entry: it is a mechanistically useful probe for connecting calcium-channel behavior with inflammatory, neuronal, and cancer-relevant phenotypes. This thought-leadership guide explains how to build a translational workflow around the Tetrandrine alkaloid while using structure-based antiviral screening as a disciplined example of what can—and cannot—be inferred across research domains.

• Caspase-3 Colorimetric Assay Kit: Evidence & Use

  2026-08-13

  The Caspase-3 Colorimetric Assay Kit measures DEVD-dependent caspase-3 activity through p-nitroaniline release at 400 or 405 nm. It provides a rapid in vitro apoptosis assay, but it does not directly measure ER stress, IRE1α-XBP1 signaling, reactive oxygen species, or in vivo apoptosis.

• GDC-0994: Reading ERK Signals Across Disease Models

  2026-08-13

  GDC-0994 is a selective ERK1/2 inhibitor for dissecting MAP kinase signaling in cancer and cholestatic liver models. This guide focuses on a practical question often missed by broad reviews: how to choose, align, and interpret pathway readouts across biologically different assays.

• Deracoxib Workflows for COX-2 Research

  2026-08-12

  Deracoxib supports mechanism-focused inflammation assays, canine pain models, and comparative oncology workflows. Its cell-type-dependent activity makes matched viability, apoptosis, and cell-cycle readouts essential for interpreting COX-2 inhibition and combination treatments.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-08-12

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines immune challenges with metabolic pathway modulation and cytokine measurement. The framework helps researchers compare immunometabolic responses across donors and cohorts while preserving the cellular interactions found in whole blood.

446 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page